Alder BioPharmaceuticals (ALDR) named biotech industry veteran Robert Azelby president and CEO of Alder, effective June 13. He also will serve on the company’s board. Azelby joins Alder from Juno Therapeutics (JUNO), where he served as executive vice president and chief commercial officer.
Thursday, June 7, 2018
Rockwell Medical updates on plans for anemia med
Rockwell Medical provided an update on the company’s commercial strategy for its innovative anemia management drug, Triferic. This update follows the completion of a thorough review of the business by the newly augmented Board of Directors. As part of this review, the Board evaluated the strategy for bringing Triferic to dialysis patients and the clinics that serve them in the U.S. and other markets around the world. After considering multiple factors and all available information, including feedback from the Center for Medicare and Medicaid Innovation, the Board concluded that the Company should move forward without assuming that it will receive a Transitional Drug Add-On Payment Adjustment for Triferic in the near term. Accordingly, the Board has concluded that it is in the best interests of patients, the clinics that serve them and Rockwell Medical’s shareholders to immediately move ahead with the commercial planning and launch of Triferic. As part of these efforts, the Board will work to ensure the Company has the appropriate resources, including recruiting additional talent, to execute on the commercialization process. In parallel with the commercial launch of Triferic, the Company intends to continue to work closely with industry leaders and policy makers to pursue a Transitional Drug Add-On Payment Adjustment for Triferic in the long term, as the Company believes this has the potential to expedite the process of getting Triferic to an even broader group of dialysis patients and clinicians.
BioMarin receives $20M in milestone payments from Pfizer
BioMarin Pharmaceutical (BMRN) announced that the company received $20M in milestone payments from Pfizer (PFE). These milestone payments were triggered by the U.S. FDA acceptance of Pfizer’s New Drug Application submission for talazoparib and by the European Medicines Agency acceptance of Pfizer’s submission of a Marketing Authorization Application for talazoparib. These milestone payments are part of an agreement made with Medivation when the company purchased talazoparib. Medivation was acquired by Pfizer.
Wednesday, June 6, 2018
Valeant upped to buy by Barclays
Barclays upgraded Valeant Pharmaceuticals (NYSE: VRX) from Equalweight to Overweight with a price target of $29.00 (from $20.00).
Subscribe to:
Posts (Atom)